Cabaletta Bio, Cellares enter 10-year commercial agreement

Cabaletta Bio (CABA) and Cellares announced a commercial agreement to supply rese-cel using Cellares’ automated Cell Shuttle and through future implementation of Cellares’ Cell Q platform. The Companies believe Cellares’ automated platforms for manufacturing and QC release can enable flexible low-cost scaling of commercial production of rese-cel to thousands of batches per year with minimal capital investment. “Autoimmune diseases require a manufacturing infrastructure that operates at an order of magnitude greater scale than traditional oncology CAR T programs. This 10-year commercial agreement with Cabaletta reflects confidence in the Cell Shuttle and Cell Q platforms,” said Fabian Gerlinghaus, Co-Founder and Chief Executive Officer, Cellares. “We look forward to continuing to support rese-cel’s journey and helping potentially bring this treatment to many more patients.”